AR047550A1 - TREATMENT OF DEPRESSION AND OTHER AFFECTIVE DISORDERS - Google Patents

TREATMENT OF DEPRESSION AND OTHER AFFECTIVE DISORDERS

Info

Publication number
AR047550A1
AR047550A1 ARP040102200A ARP040102200A AR047550A1 AR 047550 A1 AR047550 A1 AR 047550A1 AR P040102200 A ARP040102200 A AR P040102200A AR P040102200 A ARP040102200 A AR P040102200A AR 047550 A1 AR047550 A1 AR 047550A1
Authority
AR
Argentina
Prior art keywords
depression
treatment
affective disorders
gaboxadol
preparation
Prior art date
Application number
ARP040102200A
Other languages
Spanish (es)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58707228&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR047550(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR047550A1 publication Critical patent/AR047550A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso de gaboxadol en la preparacion de una composicion para el tratamiento de la depresion, y uso de gaboxadol en la preparacion de una composicion farmacéutica para ser utilizada en combinacion con un inhibidor de la reabsorcion de serotonina o cualquier otro compuesto que logre una elevacion en el nivel de serotonina extracelular.Use of gaboxadol in the preparation of a composition for the treatment of depression, and use of gaboxadol in the preparation of a pharmaceutical composition to be used in combination with a serotonin reuptake inhibitor or any other compound that achieves an elevation in the extracellular serotonin level.

ARP040102200A 2003-06-25 2004-06-23 TREATMENT OF DEPRESSION AND OTHER AFFECTIVE DISORDERS AR047550A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200300956 2003-06-25
DKPA200400016 2004-01-07

Publications (1)

Publication Number Publication Date
AR047550A1 true AR047550A1 (en) 2006-01-25

Family

ID=58707228

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102200A AR047550A1 (en) 2003-06-25 2004-06-23 TREATMENT OF DEPRESSION AND OTHER AFFECTIVE DISORDERS

Country Status (10)

Country Link
KR (1) KR20060025192A (en)
AR (1) AR047550A1 (en)
CA (2) CA2529805A1 (en)
CL (2) CL2004001607A1 (en)
EA (1) EA200600101A1 (en)
IS (1) IS8138A (en)
ME (2) MEP1908A (en)
NO (1) NO20060229L (en)
RS (1) RS20050911A (en)
TW (1) TW200509918A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3120856A1 (en) 2018-11-21 2020-05-28 Certego Therapeutics, Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
WO2021236876A2 (en) 2020-05-20 2021-11-25 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Also Published As

Publication number Publication date
IS8138A (en) 2005-11-21
NO20060229L (en) 2006-01-16
CA2529805A1 (en) 2004-12-29
CL2010000166A1 (en) 2010-07-02
TW200509918A (en) 2005-03-16
CL2004001607A1 (en) 2005-05-27
RS20050911A (en) 2007-08-03
MEP1908A (en) 2010-02-10
CA2692334A1 (en) 2004-12-29
KR20060025192A (en) 2006-03-20
EA200600101A1 (en) 2006-06-30
ME00030B (en) 2010-06-10

Similar Documents

Publication Publication Date Title
AR048878A1 (en) TOPIC COMPOSITIONS OF METADONA AND METHODS FOR USE
UY28933A1 (en) COMBINATIONS THAT INCLUDE ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS
CL2007002635A1 (en) Quinazolinone and isoquinolinone derived compounds, modulators of hpa axis activity; pharmaceutical composition comprising them; and its use in the treatment and / or prevention related to stress or depression.
ECSP11010975A (en) METHOD OF USE OF A BACILLUS SUBTILIS CEPA TO IMPROVE ANIMAL HEALTH
AR109263A2 (en) COMPOSITION INCLUDING MOXIDECTINE
UY29796A1 (en) NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS
HN2002000275A (en) DERIVATIVES OF 1.8 NAFTIRIDINE AND ITS USE FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS
HN2006000971A (en) METHODS TO PREPARE COMPOSITIONS OR DOSAGE FORMS THAT INCLUDE A GRP119 AGONIST THAT HAS THE EFFECT OF A GLP-1 SECRETAGOG
CL2018001420A1 (en) Treatment of cognitive disorders with (r) -7-chloro-n- (quinuclidin-3-yl) benzo [b] thiophene-2-carboxamide and pharmaceutically acceptable salts thereof. (divisional application 201701853)
CL2008001656A1 (en) Anti-c3b antibody; pharmaceutical composition comprising it, and its use to prevent or treat a complement-associated disorder; kit containing it.
CL2008001268A1 (en) Compounds derived from n- [6-amino-5-aryl-pyridin-2-yl] -carboxamide; pharmaceutical composition that includes them; combined pharmaceutical composition comprising them together with another additional pharmacological agent; and use them in the treatment of pain.
ECSP109852A (en) USE OF HOMO AND COPOLYMERS FOR THE STABILIZATION OF FORMULATIONS OF ACTIVE PRINCIPLES
ECSP088763A (en) NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF DEPRESSION
MXPA05013016A (en) Aboxadol for treating depression and other affective disorders.
BRPI0508680A (en) natural cooling composition, flavoring composition, ready-to-eat product, and use of a composition
AR047553A1 (en) THE COMBINATION OF A SEROTONINE AND AGOMELATINE REABSORTION INHIBITOR
CL2008003231A1 (en) Substituted 1,3-dihydro-5-isobenzofurancarbonitrile derivative compounds, selective serotonin reuptake inhibitors; pharmaceutical composition; preparation procedure; Useful in the treatment and / or prevention of premature ejaculation.
GT200600106A (en) ENDOPARASITICID AGENTS
AR056749A1 (en) ORGANOLEPTICALLY ORGANOLEPTICALLY ACCEPTABLE IBUPROPHEN DOSAGE FORMULATIONS METHODS FOR PREPARATION AND USE
CO6551744A2 (en) COMBINATION OF DRUGS WITH THEOBROMINE AND ITS USE IN THERAPY
PA8571901A1 (en) NEW PHARMACEUTICAL COMPOSITION
AR072425A1 (en) USE OF NIFURTIMOX FOR THE TREATMENT OF GIARDIASIS
CL2008001477A1 (en) Pharmaceutical composition composed of the synergistic combination of an anticonvulsant agent such as gabapentin and a non-steroidal anti-inflammatory agent such as meloxicam, the concentration ranges present for gabapentin are 3 to 300 mg and 0.1 to 30 mg for meloxicam; and use to treat neuropathic pain
ECSP12011892A (en) COMBINATION OF DRUGS WITH THEOBROMINE AND ITS USE IN THERAPY
AR062784A1 (en) TREATMENT OF THE VERTIGES WITH ACETIL -L- LEUCINA

Legal Events

Date Code Title Description
FA Abandonment or withdrawal